MENU
文章管理
2022.8.25 Glac Biotech Expands Production Capacity, Cementing Its Role as a Probiotic Industry Leader
The post-pandemic era has sparked a global health boom, and among the fastest-growing sectors is probiotics. At the center of this momentum is Glac Biotech, a company whose rapid growth and scientific rigor have fueled demand far beyond supply. To meet this surge, Glac is investing hundreds of millions of NT dollars in a bold expansion across Taiwan.
Two New Facilities: Scaling Up by Leaps and Bounds
Glac’s Chiayi plant, completed in the first quarter of the year, has already boosted annual probiotic production capacity by an impressive 8x. Meanwhile, construction is nearing completion at the Tainan plant in the Xinshi Science Park, scheduled to finish by the end of September. Once operational, the plant will double current stick-pack output from 30 million to 60 million units annually.
Together, these expansions form a powerful foundation — ensuring Glac’s cutting-edge technology and R&D achievements can continue leading the global probiotic market with the capacity to match.
Science at the Core: From Strain to Finished Product
Probiotic health starts in the gut — the body’s largest immune organ — where microbial balance is key. To support this, Glac developed its signature “10-Probiotic Complex”, long trusted by direct sales companies, pharmacists, and global brands alike.
Behind these successes is a robust infrastructure:
A probiotic strain library of several thousand strains.
A functional screening and verification platform built by PhD researchers and scientists.
Over 100 global patents safeguarding innovation.
The exclusive PRONEX® technology, ensuring the highest quality raw materials.
Clinical trials providing evidence-based validation.
Through its PRIMETEK® one-stop OEM service, Glac offers clients everything from customized formulations to finished product manufacturing — a full-spectrum solution few can match.
Leading Innovation in Probiotics and Postbiotics
Glac’s PRONULIFE® functional probiotics and Totipro® postbiotics are already redefining how these ingredients are used worldwide. Postbiotics, in particular, represent the industry’s newest frontier. By carefully fermenting functional strains and applying advanced heat-lock technology, Glac captures the nutrient-rich small molecules — branded as “益萃質” (Totipro®) — which promote beneficial bacteria growth, aid digestion, improve bowel regulation, and support immune health.
Already incorporated into a range of dietary supplements, Totipro® postbiotics have been scientifically shown to benefit gut and oral health, raising both efficacy and product value.
A Future Built on Growth and Quality
As Glac Biotech continues to scale capacity and invest in research, one thing remains constant: its commitment to providing the highest-quality probiotic and postbiotic ingredients to both Taiwanese consumers and global partners.
With expanded facilities, proven science, and relentless innovation, Glac is not only keeping pace with demand — it is setting the pace, leading the probiotic industry into a healthier, brighter future.
Two New Facilities: Scaling Up by Leaps and Bounds
Glac’s Chiayi plant, completed in the first quarter of the year, has already boosted annual probiotic production capacity by an impressive 8x. Meanwhile, construction is nearing completion at the Tainan plant in the Xinshi Science Park, scheduled to finish by the end of September. Once operational, the plant will double current stick-pack output from 30 million to 60 million units annually.
Together, these expansions form a powerful foundation — ensuring Glac’s cutting-edge technology and R&D achievements can continue leading the global probiotic market with the capacity to match.
Science at the Core: From Strain to Finished Product
Probiotic health starts in the gut — the body’s largest immune organ — where microbial balance is key. To support this, Glac developed its signature “10-Probiotic Complex”, long trusted by direct sales companies, pharmacists, and global brands alike.
Behind these successes is a robust infrastructure:
A probiotic strain library of several thousand strains.
A functional screening and verification platform built by PhD researchers and scientists.
Over 100 global patents safeguarding innovation.
The exclusive PRONEX® technology, ensuring the highest quality raw materials.
Clinical trials providing evidence-based validation.
Through its PRIMETEK® one-stop OEM service, Glac offers clients everything from customized formulations to finished product manufacturing — a full-spectrum solution few can match.
Leading Innovation in Probiotics and Postbiotics
Glac’s PRONULIFE® functional probiotics and Totipro® postbiotics are already redefining how these ingredients are used worldwide. Postbiotics, in particular, represent the industry’s newest frontier. By carefully fermenting functional strains and applying advanced heat-lock technology, Glac captures the nutrient-rich small molecules — branded as “益萃質” (Totipro®) — which promote beneficial bacteria growth, aid digestion, improve bowel regulation, and support immune health.
Already incorporated into a range of dietary supplements, Totipro® postbiotics have been scientifically shown to benefit gut and oral health, raising both efficacy and product value.
A Future Built on Growth and Quality
As Glac Biotech continues to scale capacity and invest in research, one thing remains constant: its commitment to providing the highest-quality probiotic and postbiotic ingredients to both Taiwanese consumers and global partners.
With expanded facilities, proven science, and relentless innovation, Glac is not only keeping pace with demand — it is setting the pace, leading the probiotic industry into a healthier, brighter future.
Media Coverage
Commercial Times — Aug 25, 2022 (Chinese)
www.chinatimes.com/newspapers/20220825000428-260210?chdtv
相關文章
發信給店家